Afexa Announces Results of Clinical Trial With CLL Patients

[Guest guest]

Afexa Announces Results of Clinical Trial With Chronic

Lymphocytic Leukemia Patients

http://www.marketwire.com/press-release/afexa-announces-results-of-clinical-tria\

l-with-chronic-lymphocytic-leukemia-patients-tsx-fxa-1521816.htm

or http://t.co/mpYWL7d

The results, awaiting final peer-review, demonstrated that

patients taking CVT-E002 showed a statistically significant

reduction in the incidence of moderate to severe acute

respiratory infection (ARI) symptoms (relative risk

reduction of 20.1%; p = 0.02), and a trend of reduced

incidence of moderate to severe ARI (32% vs. 39%, 95% C.I.

-18%, 4%). There was no significant difference shown for

patients with mild ARI symptoms, average number of ARI days

or antibiotic use.

In addition, when investigators analyzed immunological

response, greater seroconversion (antibody levels) was

observed against nine common upper respiratory viral

pathogens with CVT-E002 versus placebo (16% vs. 7%, p=0.04).

[Guest guest]

This is for a cold medicine called COLD-FX®

It doesn't work for CLL patients in the doses used in

this study.

They may increase dosages in a new study of CLL patients.

~chris

CLL CANADA

> Afexa Announces Results of Clinical Trial With Chronic

> Lymphocytic Leukemia Patients